Worldwide Clinical Trials To Present Webinar On Improving Screen Failure And Recruitment Rates In Alzheimer's Disease Trials
11/4/2016 8:53:56 AM
MORRISVILLE, NC, Nov. 3, 2016 – To mark Alzheimer’s Disease Awareness Month in November, Worldwide Clinical Trials (www.worldwide.com ) will host a webinar, titled “Alzheimer’s Disease Clinical Trials: Improving Screen Failure and Recruitment Rates,” on Thursday, Nov. 10, 2016 at 11 a.m. E.T.
Jeffrey Zucker, Worldwide’s Vice President of Feasibility and Recruitment Optimization, will be leading the hour-long webinar, which will discuss the main factors that contribute to failure in Alzheimer’s trials, including poor target engagement and the potential inclusion of participants who may not be appropriate, given the rationale for the therapeutic intervention.
“With more than five million Americans affected by Alzheimer’s, the need for successful clinical trials and drug development is more crucial than ever,” said Zucker. “In recognition of Alzheimer’s Disease Awareness Month, this interactive discussion will look at the historical reasons for screen failure rate, the challenges of engaging and recruiting patients in all stages of Alzheimer’s disease, and considering recent efforts to streamline enrollment in these trials, as well as the unique properties of recently introduced investigational products.”
Zucker will be joined for the webinar discussion by several of his Worldwide colleagues, including Tom Babic, M.D., Vice President, Neuroscience, and Barbara Zupancic, Director, Global Patient Recruitment and Retention.
To register for this free Worldwide Clinical Trials webinar, visit: http://go.worldwide.com/November_Alzheimers_Webinar_Registration.html.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world’s leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from medical discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit worldwide.com .
comments powered by